Gossamer to acquire Respira from Samsara Capital.

Gossamer, a clinical-stage biotech focused on pulmonary hypertension, agreed to acquire Respira Therapeutics, a private company developing RT234, an inhaled, as-needed therapy for pulmonary hypertension, from Samsara Capital. Financial terms were not disclosed.